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Abstract 
 
Glycemic variability (GV) is an indicator of glycemic control and can be evaluated by 
calculating the standard deviation (SD) of blood glucose curves. In diabetic humans, adding a 
glucagon-like peptide-1 (GLP-1) analogue to conventional therapy reduces GV. 
The objective of this study was to evaluate GV in 30 newly diagnosed diabetic cats receiving 
the GLP-1 analogue exenatide extended release (EER) and insulin.  
Blood glucose curves from a recent prospective placebo-controlled clinical trial generated 1, 
3, 6, 10 and 16 weeks after starting therapy were evaluated for GV. Cats received either EER 
(200 µg/kg) or 0.9% saline SC once weekly, insulin glargine BID and a low-carbohydrate 
diet. GV was assessed by SD. 
In the EER group, GV (mean SD [95% confidence interval]) was lower at weeks 6 (1.69 
mmol/L [.9-2.48]; P=.023), 10 (1.14 mmol/L [.66-1.62]; P=.002) and 16 (1.66 mmol/L [1.09-
2.23]; P=.019) compared to week 1 (4.21 mmol/L [2.48-5.93]) and lower compared to 
placebo at week 6 (3.29 mmol/L [1.95-4.63]; P=.037) and week 10 (4.34 mmol/L [2.43-6.24]; 
P<.000). Cats achieving remission (1.21 mmol/L [.23-2.19]) had lower GV compared to those 
without remission (2.96 mmol/L [1.97-3.96]; P=.012) at week 6. 
The combination of EER, insulin and a low-carbohydrate diet might be advantageous in the 
treatment of newly diagnosed diabetic cats. 
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Zusammenfassung 
 
Die glykämische Variabilität (GV) ist ein Indikator für die glykämische Kontrolle und kann 
mittels der Standardabweichung (SD) von Blutglukosekurven evaluiert werden. Bei 
diabetischen Menschen reduzieren GLP-1-Rezeptor-Agonisten (GLP-1-RA) zusätzlich zur 
konventionellen Therapie die GV.  
Ziel dieser Studie war die Evaluation der GV in 30 neu diagnostizierten diabetischen Katzen 
unter der Therapie mit dem GLP-1-RA Exenatide extended release (EER) und Insulin. 
Blutglukosekurven, die im Rahmen einer prospektiven Placebo-kontrollierten klinischen 
Studie 1,3,6,10 und 16 Wochen nach Therapiebeginn angefertigt wurden, wurden auf ihre GV 
untersucht. Katzen erhielten entweder EER (200 µg/kg) oder 0.9% NaCl SC einmal 
wöchentlich, Insulin Glargin BID und eine kohlenhydratarme Diät. Die GV wurde mittels der 
SD bestimmt. 
In der EER Gruppe war die GV (mittlere SD [95% Konfidenzintervall]) tiefer in den Wochen 
6 (1.69 mmol/L [.9-2.48]; P=.023), 10 (1.14 mmol/L [.66-1.62]; P=.002) und 16 (1.66 
mmol/L [1.09-2.23]; P=.019) im Vergleich zu Woche 1 (4.21 mmol/L [2.48-5.93]) und tiefer 
im Vergleich zu Placebo in den Wochen 6 (3.29 mmol/L [1.95-4.63]; P=.037) und 10 (4.34 
mmol/L [2.43-6.24]; P<.000). Katzen mit Remission (1.21 mmol/L [.23-2.19]) hatten eine 
tiefere GV im Vergleich zu Katzen ohne Remission (2.96 mmol/L [1.97-3.96]; P=.012) in der 
Woche 6. 
Die Kombination aus EER, Insulin und einer kohlenhydratarmen Diät kann vorteilhaft in der 
Behandlung neu diagnostizierter diabetischer Katzen sein. 
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Abstract
Background: Glycemic variability (GV) is an indicator of glycemic control and can be
evaluated by calculating the SD of blood glucose measurements. In humans with dia-
betes mellitus (DM), adding a glucagon-like peptide-1 (GLP-1) analogue to conven-
tional therapy reduces GV. In diabetic cats, the influence of GLP-1 analogues on GV
is unknown.
Objective: To evaluate GV in diabetic cats receiving the GLP-1 analogue exenatide
extended release (EER) and insulin.
Animals: Thirty client-owned cats with newly diagnosed spontaneous DM.
Methods: Retrospective study. Blood glucose curves from a recent prospective
placebo-controlled clinical trial generated 1, 3, 6, 10, and 16 weeks after starting ther-
apy were retrospectively evaluated for GV. Cats received either EER (200 μg/kg) or
0.9% saline SC once weekly, insulin glargine and a low-carbohydrate diet. Mean blood
glucose concentrations were calculated and GV was assessed by SD. Data were ana-
lyzed using nonparametric tests.
Results: In the EER group, GV (mean SD [95% confidence interval]) was lower at
weeks 6 (1.69 mmol/L [0.9-2.48]; P = .02), 10 (1.14 mmol/L [0.66-1.62]; P = .002)
and 16 (1.66 mmol/L [1.09-2.23]; P = .02) compared to week 1 (4.21 mmol/L
[2.48-5.93]) and lower compared to placebo at week 6 (3.29 mmol/L [1.95-4.63];
P = .04) and week 10 (4.34 mmol/L [2.43-6.24]; P < .000). Cats achieving remission
Abbreviations: DM, diabetes mellitus; EER, exenatide extended release; GLP-1, glucagon-like peptide-1; GV, glycemic variability.
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(1.21 mmol/L [0.23-2.19]) had lower GV compared to those without remission
(2.96 mmol/L [1.97-3.96]; P = .01) at week 6.
Conclusions and Clinical Importance: The combination of EER, insulin, and a low-
carbohydrate diet might be advantageous in the treatment of newly diagnosed
diabetic cats.
K E YWORD S
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1 | INTRODUCTION
Glycemic variability (GV) refers to glycemic excursions, including epi-
sodes of hypoglycemia and hyperglycemia, during the course of a day
or on different days.1 In humans with diabetes mellitus (DM), GV is an
indicator of glycemic control.1,2 High GV is considered a risk factor for
hypoglycemia, microvascular complications, neuropathy, retinopathy,
stroke and all-cause mortality.2-7 Currently, there is lack of a consen-
sus on the gold-standard method for measuring GV, and several indi-
cators are proposed.1,3,4 The SD, which describes the dispersion of
values around mean blood glucose, is considered the simplest approach
and is commonly used for the evaluation of GV in people.3,8
Incretins such as glucagon-like peptide-1 (GLP-1) are hormones
that are released from the gastrointestinal tract during food intake,
leading to increased glucose-stimulated insulin secretion. GLP-1 also
inhibits glucagon secretion, slows gastric emptying, and enhances sati-
ation.9-11 Moreover, it increases the proliferation of pancreatic β-cells
and decreases their apoptosis, thereby increasing β-cell mass, in
rodent models.11
In humans with type 2 DM, administration of the long-acting
GLP-1 analogue exenatide extended release (EER) and metformin sig-
nificantly improves GV compared to metformin alone.12 Furthermore,
the use of a GLP-1 analogue on a background treatment of metformin
and basal insulin therapy might have a greater effect in reducing GV
than prandial insulin.13
In cats, GV has just started to be explored.14 GV is higher in dia-
betic cats experiencing posthypoglycemic hyperglycemia during insu-
lin treatment compared to diabetic cats without posthypoglycemic
hyperglycemia. Increased GV in cats with posthypoglycemic hypergly-
cemia is associated with higher insulin dose, higher serum fruc-
tosamine concentrations, and decreased glycemic control.14
Most cats with DM have type 2-like DM. Therefore, it is hypothe-
sized that incretins could be of similar benefit in the treatment of DM
in cats as in that of people.15 EER enhances insulin secretion in
healthy cats and treatment appears to be safe in both healthy and dia-
betic cats.16,17 The use of GLP-1 analogues in diabetic cats has been
examined in 2 studies17,18 and treatment with exenatide is safe, asso-
ciated with significant weight loss and a decreased requirement for
exogenous insulin.18 Once-weekly administration of the long-acting
EER has beneficial effect on remission and metabolic control
(no clinical signs, serum fructosamine concentration between 350 and
450 μmol/L, blood glucose concentration between 4.4 and 15 mmol/
L) in insulin-treated cats with DM. 17
To date, the role of GLP-1 analogues on GV has not been investi-
gated in diabetic cats. The objective of the present study was to eval-
uate GV in diabetic cats receiving the GLP-1 analogue EER and
insulin. We hypothesized that EER would lead to a reduction in GV
and that cats achieving remission would have lower GV compared to
cats without remission.
2 | MATERIALS AND METHODS
2.1 | Study design
An evaluation of blood glucose curves from a recently published pro-
spective placebo-controlled clinical trial was performed.17 Cats with
newly diagnosed DM admitted from January 2013 to January 2015 to
the Clinic for Small Animal Internal Medicine of the University of
Zurich and the Department of Veterinary Medical Sciences, University
of Bologna were included in the trial. The diagnosis of DM was based
on clinical signs (eg, polyuria, polydipsia, weight loss), fasting hyperglyce-
mia, glucosuria, and increased serum fructosamine concentration.17,19
Exclusion criteria were previous treatment with insulin or any
other antidiabetic medication for >4 weeks before admission, as well
as glucocorticoid and progestagen treatment within 3 months prior to
admission. Furthermore, cats with concurrent diseases (eg, renal dis-
ease, gastrointestinal disorder, heart disease, other endocrinopathies
or neoplasia) were excluded. Cats with ketoacidosis or pancreatitis
were included in the study if clinical signs had resolved and their gen-
eral condition had improved within 48 hours of treatment. All cats
were thoroughly evaluated (physical examination, complete blood count,
serum chemistry, urinalysis, blood pressure measurement, abdominal and
thoracic radiography, abdominal ultrasonography).
The 30 client-owned cats with newly diagnosed spontaneous DM
included in the study were alternately assigned to 1 of 2 treatment
groups. Fifteen cats were treated with EER (Bydureon; Amylin Pharma-
ceuticals, San Diego, California; 200 μg/kg) and 15 cats with 0.33 mL of
0.9% saline (placebo), administered subcutaneously by the owner or a
veterinarian, once weekly. Owners were blinded to the treatment group
of their cats. Both groups received insulin glargine (Lantus, Sanofi Aventis,
Meyrin, Switzerland) twice daily subcutaneously and a low-carbohydrate
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diet (DM Purina Veterinary Diets; Medical Solution, Steinhausen, Switzer-
land). EER was administered for at least 16 weeks. In cases of remission,
EER treatment was continued for another 4 weeks after cessation of insu-
lin treatment.
The insulin dose was adjusted based on clinical signs, results of
physical examination, blood glucose curves and serum fructosamine
concentration. In cats achieving remission, the insulin dose was
decreased in increments of 0.5 IU per treatment, once weekly. The
last dosage before insulin was discontinued was 0.5 IU once daily,
for at least 1 week.17
Follow-up evaluations were performed 1, 3, 6, 10, and 16 weeks
after starting therapy in all cats. For the purpose of the present study,
blood glucose curves obtained at these time points were evaluated
for GV. Blood glucose curves consisted of capillary glucose values
measured every 2 hours for 8-12 hours (with each curve consisting of
at least 4 measurements) using the validated portable blood glucose
meter (AlphaTRAK, Zoetis, Parsippany, New Jersey).20 Hypoglycemia
was defined as a blood glucose concentration ≤3.6 mmol/L.17 Remis-
sion was defined as absence of clinical signs of DM and normal blood
glucose (4-9 mmol/L) and fructosamine (<350 μmol/L) concentrations
for at least 4 weeks after cessation of insulin therapy.21 Further
details regarding the previous study are described elsewhere.17
2.2 | Statistical analysis
All cats from the previous study17 were included in this retrospective
evaluation of blood glucose curves. GV was evaluated as reported
previously.14 Mean blood glucose concentrations of each blood glu-
cose curve generated during follow-up evaluations were calculated.
As a marker for GV, their corresponding SD was calculated. Both
mean blood glucose concentrations and SD of each blood glucose
curve were compared between treatment groups and between cats
achieving or not achieving remission at each time point during follow-
up. The latter calculations (remission vs nonremission) were carried
out in the whole study population as well as within each treatment
group if the number of cases with and without remission was ≥5. In
addition, differences in mean blood glucose concentrations and GV
between week 1 and follow-up evaluations were calculated within
each treatment group and within the group of cats achieving and not
achieving remission. Regarding the comparison within the group of
cats achieving remission, blood glucose curves obtained during remis-
sion were excluded from analysis to avoid any bias on GV, as cats in
remission per se are expected to have lower GV. Though excluded
from analysis, subsequent blood glucose curves from these cats were
evaluated to ensure that cats were still in remission and that the
criteria of remission (normal glucose concentrations for at least
4 weeks) were fulfilled.
Distribution of sex and breed, frequency of previous antidiabetic
medication or ketoacidosis between the treatment groups were com-
pared using Fisher exact test. Fisher exact test was also used to com-
pare the frequency of hypoglycemic episodes and the rate and onset
of remission.17 The rate of remission was defined as the number of
cats achieving remission within the 16-weeks study period.
Differences for age, body weight and daily insulin dosage were
analyzed using the Mann-Whitney U test or t test.17 Comparisons
between groups were made by means of the Kruskal-Wallis test
and the Mann-Whitney U test, comparisons within groups with the
Wilcoxon paired test. Level of significance was set at P < .05. All
statistical analyses were performed using 2 commercial statistical
programs (IBM SPSS Statistics Version 25.0., Armonk, New York




The EER group consisted of 12 (80%) domestic short- or longhair and
3 (20%) purebred cats including 2 Maine Coons and 1 Norwegian For-
est Cat; 9 (60%) were neutered males, 1 (7%) was an intact male and
5 (33%) were spayed females. Median age was 9.3 years (range,
4.3-14) and median body weight was 5.3 kg (range, 4.4-7.4).17
The placebo group consisted of 14 (93%) domestic short- or long-
hair and 1 (7%) purebred (Exotic) cats; 5 (33%) cats were neutered
males and 10 (67%) were spayed females. Median age was 10 years
(range, 2.6-15) and median body weight was 4.5 kg (range, 2.7-8.3).17
There were no significant differences between the 2 groups
regarding age, body weight, breeds, sex, or frequency of cats with pre-
vious ketoacidosis or overall antidiabetic medication. Nine cats had
ketoacidosis, which resolved within 1-2 days of treatment (3 in the
EER group and 6 in the placebo group; P = .43).17
Before inclusion, 8 (53%) cats in the EER group and 10 (67%) in the
placebo group received antidiabetic treatment, respectively (P = .71).
Sixteen cats received some form of insulin treatment within <4 weeks
before inclusion. Ten cats (6 in EER group and 4 in placebo group) were
treated with insulin glargine (Lantus) only and 3 cats (1 in EER group
and 2 in placebo group) with lente-type insulin (Caninsulin/Vetinsulin,
MSD Merck) only. Two cats (both in placebo group) were treated with
a combination of short-acting insulin aspart (NovoRapid, Novo Nordisk
Pharma AG) and insulin glargine (Lantus). One cat (EER group) received
lente-type insulin (Caninsulin/Vetinsulin) first and insulin glargine (Lantus)
afterwards. Furthermore, 1 cat in the placebo group was treated with the
sulfonylurea glipizide prior to inclusion and 1 cat in the EER group
received only an antidiabetic diet.17
The median insulin glargine dose administered during the study
period did not differ between groups (EER 0.41 IU/kg/day; range,
0.11-0.88; placebo 0.38 IU/kg/day; range, 0.22-1.5; P = .66 if phases
of remission were excluded; EER 0.36 IU/kg/day; range, 0.07-0.88;
placebo 0.33 IU/kg/day; range, 0.13-1.5; P = .49 if phases of remis-
sion were included).17 There was also no significant difference in
baseline results of CBC, biochemical profile, urinalysis and blood pres-
sure measurement.17
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3.2 | Glycemic variability in treatment groups
Reevaluations were scheduled at 1, 3, 6, 10, and 16 weeks after
starting treatment. In total, 132 blood glucose curves were available
for comparing treatment groups (64 in the placebo group and 68 in
the EER group). In 18 cats (60%) blood glucose curves were available
from each reevaluation. In 12 cats (40%; 6 cats in the placebo group
and 6 cats in the EER group), the following number of glucose curves
were available: in 8 cats 4 curves each, in 2 cats 3 curves each, and in
another 2 cats 2 curves each. In the placebo and EER groups, 11 and
7 glucose curves were missing, respectively.
Mean blood glucose concentrations are listed in Table 1. Means
(mean [95% confidence interval]) were significantly lower in the EER group
than in the placebo group at weeks 6 (EER 5.1 mmol/L [4.22-5.98] vs pla-
cebo 12.96 mmol/L [9.09-16.84]; P < .000) and 10 (EER 5.96 mmol/L
[4.31-7.61] vs placebo 11.67 mmol/L [7.14-16.2]; P = .002). In the EER
group, 14 of 15 cats (93%) and in the placebo group 12 of 15 cats (80%)
had episodes of hypoglycemia based on blood glucose curves. The fre-
quency of hypoglycemic episodes was not different between both groups
(P = .6).17 The lowest blood glucose concentrations recorded in the EER
group was 1.4 mmol/L and in the placebo group 1.8 mmol/L, respectively.
In the EER group, the SD as a marker for GV (mean SD [95% confi-
dence interval]) was significantly lower at weeks 6 (1.69 mmol/L [0.9-2.48];
P = .02), 10 (1.14 mmol/L [0.66-1.62]; P = .002) and 16 (1.66 mmol/L
[1.09-2.23]; P = .02) compared to week 1 (4.21 mmol/L [2.48-5.93]). In the
placebo group, there were no significant differences in GV from week 1 to
any of the other time points. Comparison of the 2 groups revealed sig-
nificantly lower GV in the EER group compared to the placebo group
at week 6 (EER 1.69 mmol/L [0.9-2.48] vs placebo 3.29 mmol/L
[1.95-4.63]; P = .04) and week 10 (EER 1.14 mmol/L [0.66-1.62] vs
placebo 4.34 mmol/L [2.43-6.24]; P < .000) (Figure 1).
3.3 | Glycemic variability in cats with and without
remission
To compare cats with and without remission, 7 blood glucose curves
(from 5 cats) from the remission group were excluded from further
analysis because they were generated during remission. In the EER
group, 6 of 15 (40%) cats achieved remission after a median of
11 weeks (range, 10-14), while in the placebo group, 3 of 15 (20%)
cats achieved remission after a median time of 10 weeks (range, 8-10)
following initiation of treatment. There was no difference in the rate
and time to achieve remission between the EER and placebo group
(rate P = .43; onset P = .17).17 All 9 cats that achieved remission also
stayed in remission during the whole study period of 16 weeks. After
the end of the study 4 cats (3 in EER group, 1 in placebo) experienced
a relapse after a median of 37 months (range, 4-65 months) after
remission-onset. The remaining 5 cats (3 in EER group, 2 in placebo
group) stayed in remission for a median of 15 months (range, 7-24)
follow-up time.
Results on the mean blood glucose concentrations in cats with
and without remission are listed in Tables 2 and 3.
TABLE 1 Mean blood glucose concentrations (in mmol/L) in the EER and the placebo group
EER Placebo
Reevaluation Mean (mmol/L) SD (mmol/L) n Mean (mmol/L) SD (mmol/L) n P
1 16.6 7.7 15 16.1 8.2 13 .77
3 13.4 6.9 13 12.3 7.4 14 .77
6 5.1 1.5 13 13.0 6.7 15 .000
10 6.0 3.0 15 11.7 6.7 11 .002
16 7.0 1.5 12 8.8 4.5 11 .78
Abbreviations: EER, exenatide extended release; n, number of cats.
F IGURE 1 Standard deviation as marker for glycemic variability in
the exenatide extended release (EER) and in the placebo group. Dots
(EER group; n = 15) and squares (placebo group; n = 15) represent
means and bars represent corresponding SDs. Horizontal bars
represent significant differences in glycemic variability (GV) between
reevaluations and groups. In the EER group, GV is significantly lower
at weeks 6, 10, and 16 compared to week 1, whereas no difference
was revealed in the placebo group. GV is significantly lower in the
EER group compared to the placebo group at weeks 6 and
10. *P < .05
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Within the whole group of cats achieving remission, the SD as a
marker for GV was significantly lower at week 6 (1.21 mmol/L [0.23-2.19])
compared to week 1 (3.56 mmol/L [1.77-5.35]; P = .02). Within the whole
group of cats not achieving remission, no difference in GV was observed
between week 1 and any other time point. When cats with and without
remission were compared, GV was significantly lower in the remission
group at week 6 (remission 1.21 mmol/L [0.23-2.19] vs nonremission
2.96 mmol/L [1.97-3.96]; P = .01) (Figure 2).
When only the EER group was evaluated, within cats achieving
remission, GV significantly decreased from week 1 (3.67 mmol/L
[0.87-6.47]) to week 6 (0.63 mmol/L [0.3-0.95]; P = .04). Within the
group that did not achieve remission, there was a significant decrease
from week 1 (4.56 mmol/L [1.88-7.25]) to week 10 (1.36 mmol/L
[0.54-2.17]; P = .04). When cats with and without remission from the
EER group were compared, GV was significantly lower in the remis-
sion group at week 6 (remission 0.63 mmol/L [0.3-0.95] vs non-
remission (2.32 mmol/L [1.24-3.4]; P = .008) (Figure 3). In the placebo
group, the comparison of GV between cats achieving and not achiev-
ing remission was not performed due to the limited number of cases
(only 3 cats in remission).
4 | DISCUSSION
The present study evaluates GV in diabetic cats receiving the GLP-1
analogue EER once weekly. EER was given in addition to standard
treatment consisting of insulin glargine and a low-carbohydrate diet.
When compared to values for week 1, GV in the EER group was sig-
nificantly lower from 6 weeks of therapy until the end of the study at
week 16, whereas GV did not change in the placebo group. Compari-
son between the 2 groups revealed significantly lower GV in the EER
group 6 and 10 weeks after initiating therapy.
The importance of GV as a marker for glycemic control in people
has increased.1,2,4
Glycated hemoglobin is considered the gold standard for assessing
long-term glycemic control in people over time.1,4 However, the variable
does not take into account short-term fluctuations in blood glucose con-
centrations which increase the risk for both hypo- and hyperglycemia;
moreover, even patients with optimally glycated hemoglobin can have
substantial daily fluctuations in blood glucose levels.1,2,4,22 Perhaps more
importantly, GV, like mean blood glucose, is independently and strongly
predictive of hypoglycemia, while glycated hemoglobin is a poor predictor
of hypoglycemic events.23 Increased GV has several implications for the
development of chronic diabetic complications, all-cause mortality and
quality of life.1,2,4 One important treatment goal in human medicine
therefore is to avoid multiple blood glucose fluctuations as they can be
even more harmful than stable chronic hyperglycemia.1,2
Currently, there is no gold-standard method for the assessment
of GV, and various indices, each with its own advantages and disad-
vantages, are proposed.1,2,4 We used the variable SD in accordance
with previous studies of our research group because in human medi-
cine it is widely used and simple to calculate.2,8 One limitation of SD
is that it implies that measures of glucose concentrations are normally
distributed, which is not always the case.1,8 However, SD remains a
fairly robust measure because a linear relation has been established
between the interquartile range and the SD.1,24 Because of the con-
sistent shape of the glucose distribution in many circumstances, it is
often possible to transform the data, so it becomes nearly symmetri-
cal.24 Furthermore, there is a high degree of correlation between SD
and other markers for GV25-32 and it takes all glycemic oscillations
into account. Standard deviation has recently been recommended as a
key variable together with the coefficient of variation (SD divided by the
mean) in a consensus on continuous glucose monitoring in people.33
In cats, the concept of GV is not yet well studied. Fluctuations are
frequently observed in blood glucose curves in diabetic cats and dia-
betic cats with posthypoglycemic hyperglycemia have higher GV.14 In
contrast, posthypoglycemic hyperglycemia does not occur in healthy
experimental cats treated with insulin, which suggests that they are
able to fine-tune glycemia.14 Good metabolic control is seen in 70%
of cats without posthypoglycemic hyperglycemia, but in only 6.7% of
cats with this phenomenon.14 Cats with posthypoglycemic hypergly-
cemia are considered difficult to control, and in the long-term require
continued dose adjustments because of reoccurring hypoglycemic
nadirs.34
In the present study, cats in the EER group had lower GV com-
pared to placebo. These findings are in agreement with several human
studies, where positive effects of GLP-1 analogues on GV are already
known. For example, there is a GV-lowering effect of exenatide in the
short-term in human type 2 diabetics.35 Furthermore, exenatide treat-
ment results in greater improvements in GV than does insulin glargine
in patients with DM using metformin, a sulfonylurea or both concur-
rently.36,37 In contrast, in human overweight and obese patients
TABLE 2 Mean blood glucose concentrations (in mmol/L) in all cats: comparison between remission and nonremission
Remission Nonremission
Reevaluation Mean (mmol/L) SD (mmol/L) n Mean (mmol/L) SD (mmol/L) n P
1 14.0 7.8 9 17.6 7.8 19 .27
3 7.8 5.7 8 14.8 6.6 20 .01
6 7.2 6.2 7 9.9 6.3 20 .18
10 5.9 2.7 6 9.7 6.1 18 .08
16 6.2 0.0 1 8.5 3.8 16 .39
Abbreviation: n, number of cats.
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inadequately controlled by metformin, there is similar efficacy between
exenatide and insulin glargine in terms of GV, but exenatide has a
greater effect on body weight and body mass index.38
The improvement of GV in EER-treated cats could be explained
by the physiologic effects of GLP-1, especially the glucose-dependent
stimulation of insulin secretion and concomitant suppression of gluca-
gon.11,35 By enhancing insulin production and secretion after a meal,
incretin hormones serve to suppress postprandial hyperglycemia39
and therefore glycemic fluctuations. Furthermore, GLP-1 analogues
lead to decelerated gastric emptying, which further attenuates increases
in meal-associated blood glucose concentrations.11
In the whole population of cats, GV was lower at week 6 com-
pared to week 1 only in the group that achieved remission, whereas it
did not change in the nonremission group. When the 2 groups were
compared, GV was significantly lower in those achieving remission
6 weeks after initiating therapy.
In cats with posthypoglycemic hyperglycemia, only 10% of cats
achieve remission compared to almost 66% without it.14 Furthermore,
there is less day-to-day variability in blood glucose concentrations in
diabetic cats with good glycemic control compared to cats with mod-
erate or poor control.40 GLP-1 analogues in diabetic cats slightly
improve remission rates.17,18 In newly diagnosed and drug-naive
human type 2 DM patients who achieve glycemic remission, sequen-
tial treatment with exenatide for 12 weeks induces significantly higher
maintenance of 1- and 2-year glycemic remission rates as compared
to short-term intensive insulin therapy alone. This effect is no longer
apparent after cessation of exenatide.41
It is likely that diabetic remission in cats occurs through reversal
of glucotoxicity and that effective control of hyperglycemia in diabetic
patients decreases the deleterious effects of glucotoxicity on
TABLE 3 Mean blood glucose concentrations (in mmol/L) in the EER group: comparison between remission and nonremission
Remission Nonremission
Reevaluation Mean (mmol/L) SD (mmol/L) n Mean (mmol/L) SD (mmol/L) n P
1 14.3 8.8 6 18.2 7.1 9 .29
3 8.3 7.5 5 16.5 4.5 8 .06
6 4.5 1.2 5 5.5 1.5 8 .31
10 4.5 0.9 4 6.7 3.7 9 .17
16 6.2 0.0 1 7.3 1.5 8 .25
Abbreviations: EER, exenatide extended release; n, number of cats.
F IGURE 2 Standard deviation as marker for glycemic variability in
all cats with and without remission. Triangles (cats with remission;
n = 9) and diamonds (cats without remission; n = 21) represent means
and bars represent corresponding SDs. Horizontal bars represent
significant differences in glycemic variability (GV) between
reevaluations and groups. In the remission-group, GV is significantly
lower at week 6 compared to week 1, whereas no difference was
revealed in the nonremission group. GV is significantly lower in the
remission group compared to the nonremission group at
week 6. *P < .05
F IGURE 3 Standard deviation as marker for glycemic variability in
exenatide extended release group with and without remission.
Triangles (cats with remission; n = 6) and diamonds (cats without
remission; n = 9) represent means and bars represent corresponding
SDs. Horizontal bars represent significant differences in glycemic
variability (GV) between reevaluations and groups (continuous
line = remission group; interrupted line = nonremission group). In the
remission group GV is significantly lower at week 6 compared to
week 1. In the nonremission group GV was significantly lower at week
10 compared to week 1. GV is significantly lower in the remission
group compared to the non-remission group at week 6. *P < .05
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pancreatic β-cells and increases the chance of remission.9,42 After
rapid recovery from glucotoxicity through insulin glargine, EER might
further improve and maintain β-cell function and reverse subsequent
insulin-resistance. Results of the present and previous studies14,40
suggest that lowering GV should be a preferential goal in the treat-
ment of diabetic cats in order to increase the likelihood of remission.
To date, there is no single diagnostic test or cat characteristic identi-
fied that reliably predicts remission in diabetic cats at the time of diag-
nosis.42 Although further studies are needed, results of the present
study could provide useful information to answer the question as to
whether GV could be a potential predictor of remission in diabetic cats.
In the current study, GV was significantly lower in the EER group
compared to placebo at weeks 6 and 10.
This exposure time might be needed to reverse glucotoxicity. In
human type 2 DM patients, β-cell function normalizes after an 8-week-
course of dietary energy restriction.43 Furthermore, in humans with
type 2 DM, partial restoration of β-cell function is achieved after
4 weeks of near-normalization of plasma glucose concentrations.44
In addition to GV, mean blood glucose values at certain time
points were significantly lower in cats in the EER group compared to
placebo as well as in cats with remission compared to cats without
remission. It is important to note that the number of hypoglycemic
events did not differ between groups.17 This is in line with previous
studies on GLP-1 analogues in healthy and diabetic cats.18,45 In people
and experimental animals, exenatide ceases to stimulate insulin secre-
tion once euglycemia is restored.46,47 Furthermore, GLP-1 analogues
also suppress glucagon secretion in a glucose-dependent manner,11
which together could be a possible explanation for the low risk of
hypoglycemia in GLP-1 treated cats. In contrast to the results of our
study, there are no differences in mean blood glucose between the
treatment group compared to placebo in a previous study.18 However,
the results of the 2 studies cannot be directly compared because the
present study used once-weekly EER and the previous examined
effects of the short-acting exenatide with twice daily injections. Fur-
thermore, with only 8 cats and 6 weeks of treatment in the latter
study, the power and time span could have been too small to detect
differences.
Long-term GLP-1 analogues have become widely used in human
medicine. In diabetic cats, the safety of the long-acting EER has
already been assessed.17 Recently, a GLP-1 analogue suitable for
once-monthly administration in the cat was presented.48 We believe
that once-weekly or even once-monthly injections would be conve-
nient additional treatment options in diabetic cats.
When discussing the results of the present study, some limita-
tions need to be considered. First, a relatively small number of cats
were evaluated. We consider this study an important starting point
which is intended to serve as a basis for further studies on GLP-1
agonists and its potential to reduce GV. Despite the relatively small
number of cats, we were able to show significantly lower GV in EER-
treated cats and cats with remission compared to placebo and cats
without remission, respectively. Furthermore, the number of blood
glucose curves was limited, so in some cats, severe blood glucose fluc-
tuations at certain time points after starting therapy might have been
missed. This limitation seems to be of minor relevance because the
number of cats with missing blood glucose curves was comparable in
both treatment groups. Also, short episodes of hypo- und hyperglyce-
mia might have been missed when using a portable blood glucose
meter instead of continuous blood glucose monitoring. Further, the
study period was 16 weeks and it is possible that more cats would
have achieved remission afterwards. Lastly, GV was evaluated in
newly diagnosed diabetic cats without concurrent diseases, so the
results of the present study cannot be extrapolated to the general
population of diabetic cats and further studies are needed to assess
GV in diabetic cats with concurrent diseases.
ACKNOWLEDGMENT
No funding was received for this study.
CONFLICT OF INTEREST DECLARATION
Eric Zini serves as Associate Editor for the Journal of Veterinary Inter-
nal Medicine. He was not involved in review of this manuscript.
OFF-LABEL ANTIMICROBIAL DECLARATION
Authors declare no off-label use of antimicrobials.
INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE
(IACUC) OR OTHER APPROVAL DECLARATION
Authors declare no IACUC or other approval was needed.
HUMAN ETHICS APPROVAL DECLARATION
Authors declare human ethics approval was not needed for this study.
ORCID
Anna L. Krämer https://orcid.org/0000-0002-3174-7524
Federico Fracassi https://orcid.org/0000-0003-3121-2199
Felicitas S. Boretti https://orcid.org/0000-0001-6793-8464
Nadja S. Sieber-Ruckstuhl https://orcid.org/0000-0002-8256-0137
Eric Zini https://orcid.org/0000-0002-7580-1297
REFERENCES
1. Suh S, Kim JH. Glycemic variability: how do we measure it and why is
it important? Diabetes Metab J. 2015;39:273-382.
2. Frontoni S, Di Bartolo P, Avogaro A, et al. Glucose variability: an
emerging target for the treatment of diabetes mellitus. Diabetes Res
Clin Pract. 2013;102:86-95.
3. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c- inde-
pendent risk factor for diabetic complications. JAMA. 2006;295(14):
1707-1708.
4. Umpierrez GE, Kovatchev BP. Glycemic variability: how to measure
and its clinical implication for type 2 diabetes. Am J Med Sci. 2018;
356(6):518-527.
5. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN, for the
DCCT/EDIC Research Group. Effect of glycemic exposure on the risk
of microvascular complications in the diabetes control and complica-
tions trial—revisited. Diabetes. 2008;57(4):995-1001.
6. Zinman B, Marso SP, Christiansen E, et al. Day-today fasting glyce-
mic variability in DEVOTE: associations with severe hypoglycemia
and cardiovascular outcomes (DEVOTE 2). Diabetologia. 2018;61:
48-57.
KRÄMER ET AL. 7
7. Lin CC, Yang CP, Li CI, et al. Visit-to-visit variability of fasting plasma
glucose as a predictor of ischemic stroke: competing risk analysis in a
national cohort of Taiwan diabetes study. BMC Med. 2014;26:165.
8. Service FJ. Glucose variability. Diabetes. 2013;62(5):1398-1404.
9. Reusch CE. Feline diabetes mellitus. In: Feldman EC, Nelson RW,
Reusch CE, Scott-Moncrieff JC, eds. Textbook of Canine and Feline
Endocrinology. 4th ed. St. Louis, MO: Saunders; 2015:258-314.
10. Gilor C, Graves TK, Gilor S, Ridge TK, Rick M. The GLP-1 mimetic
exenatide potentiates insulin secretion in healthy cats. Domest Anim
Endocrinol. 2011;41:42-49.
11. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroen-
terology. 2007;132(6):2131-2157.
12. Frias JP, Nakhle S, Ruggles JA, et al. Exenatide once weekly
improved 24-hour glucose control and reduced glycemic variabil-
ity in metformin-treated patients with type 2 diabetes: a random-
ized, placebo-controlled trial. Diabetes Obes Metab. 2016;19:
40-48.
13. FLAT-SUGAR Trial Investigators. Glucose variability in a 26-week
randomized comparison of mealtime treatment with rapid-acting
insulin versus GLP-1 agonist in participants with type 2 diabetes at
high cardiovascular risk. Diabetes Care. 2016;39(6):973-981.
14. Zini E, Salesov E, Dupont P, et al. Glucose concentrations after
insulin-induced hypoglycemia and glycemic variability in healthy and
diabetic cats. J Vet Intern Med. 2018;32(3):978-985.
15. Reusch CE, Padrutt I. New incretin hormonal therapies in humans rel-
evant to diabetic cats. Vet Clin N Am Small Anim Pract. 2013;35:
211-224.
16. Padrutt I, Lutz TA, Reusch CE, Zini E. Effects of the glucagon-like
peptide-1 (GLP-1) analogues exenatide, exenatide extended-release,
and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glu-
cose metabolism in healthy cats. Res Vet Sci. 2015;99:23-29.
17. Riederer A, Zini E, Salesov E, et al. Effect of the glucagon-like
peptide-1 analogue rxenatide extended release in cats with newly
diagnosed diabetes mellitus. J Vet Intern Med. 2016;30(1):92-100.
18. Scuderi MA, Ribeira Petito M, Unniapan S, et al. Safety and efficacy
assessment of a GLP-1 mimetic: insulin glargine combination for
treatment of feline diabetes mellitus. Domest Anim Endocrinol. 2018;
65:80-89.
19. Tschuor F, Zini E, Schellenberg S, et al. Remission of diabetes mellitus
in cats cannot be predicted by the arginine stimulation test. J Vet
Intern Med. 2011;25:83-89.
20. Zini E, Moretti S, Tschuor F, et al. Evaluation of a new portable glu-
cose meter designed for the use in cats. Schweiz Arch Tierheilkd. 2009;
15:448-451.
21. Sieber-Ruckstuhl NS, Kley S, Tschuor F, et al. Remission of diabetes
mellitus in cats with diabetic ketoacidosis. J Vet Intern Med. 2008;22:
1326-1332.
22. Chon S, Lee YJ, Fraterrigo G, et al. Evaluation of glycemic variability
in well-controlled type 2 diabetes mellitus. Diabetes Technol Ther.
2013;15:455-460.
23. Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glu-
cose and glucose variability to the risk of multiple episodes of
hypoglycaemia in type 1 diabetes. Diabetologia. 2007;50:2553-2561.
24. Rodbard D. Optimizing display, analysis, interpretation and utility of
self-monitoring of blood glucose (SMBG) data for management of
patients with diabetes. J Diabetes Sci Technol. 2007;1:62-71.
25. Rodbard D. Glycemic variability: measurement and utility in clinical
medicine and research -one viewpoint. Diabetes Technol Ther. 2011;
13(11):1077-1080.
26. Jung HS. Clinical implications of glucose variability: chronic
complications of diabetes. Endocrinol Metab (Seoul). 2015;30(2):
167-174.
27. Borg R, Kuenen JC, Carstensen B, et al. ADAG study group: HbA1c
and mean blood glucose show stronger associations with cardiovas-
cular disease risk factors than do postprandial glycaemia or glucose
variability in persons with diabetes: the A1C-derived average glucose
(ADAG) study. Diabetologia. 2011;54:69-72.
28. Rodbard D. Interpretation of continuous glucose monitoring data: gly-
cemic variability and quality of glycemic control. Diabetes Technol
Ther. 2009;11(suppl 1):S55-S57.
29. Rodbard D. New and improved methods to characterize glycemic var-
iability using continuous glucose monitoring. Diabetes Technol Ther.
2009;11:551-565.
30. Rodbard D, Bailey T, Jovanovic L, Zisser H, Kaplan R, Garg SK.
Improved quality of glycemic control and reduced glycemic variability
with use of continuous glucose monitoring. Diabetes Technol Ther.
2009;11:717-723.
31. Rodbard D, Jovanovic L, Garg S. Responses to continuous glucose
monitoring in subjects with type 1 diabetes using continuous subcu-
taneous insulin infusion or multiple daily injections. Diabetes Technol
Ther. 2009;11:757-765.
32. Baghurst PA. Calculating the mean amplitude of glycemic excursion
from continuous glucose monitoring data: an automated algorithm.
Diabetes Technol Ther. 2011;13:296-302.
33. Danne T, Nimri R, Battelino T, et al. International consensus on use of
continuous glucose monitoring. Diabetes Care. 2017;40(12):1631-
1640.
34. Roomp K, Rand J. Rebound hyperglycemia in diabetic cats. J Feline
Med Surg. 2016;18(8):587-596.
35. Irace C, Fiorentino R, Carallo C, Scavelli F, Gnasso A. Exenatide
improves glycemic variability assessed by continuous glucose moni-
toring in subjects with type 2 diabetes. Diabetes Technol Ther. 2011;
13(12):1261-1263.
36. Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of
exenatide and titrated insulin glargine in adult patients with type
2 diabetes previously uncontrolled with metformin or a sulfonylurea:
a multinational, randomized, open-label, 2-period, crossover nonin-
feriority trial. Clin Ther. 2007;29(11):2333-2348.
37. McCall AL, Cox DJ, Brodows R, et al. Reduced daily risk of glycemic
variability: comparison of exenatide with insulin glargine. Diabetes
Technol Ther. 2009;11(6):339-344.
38. Yin TT, Bi Y, Shen SM, et al. Comparison of glycemic variability in Chi-
nese T2DM patients treated with exenatide or insulin glargine: a ran-
domized controlled trial. Diabetes Ther. 2018;9(3):1253-1267.
39. Seyfert TM, Brunker JD, Maxwell LK, et al. Effects of a glucagon-like
peptide-1 mimetic (exenatide) in healthy cats. Int J Appl Res Vet Med.
2012;10(2):147-156.
40. Alt N, Kley S, Haessig M, Reusch CE. Day-to-day variability of blood
glucose concentration curves generated at home in cats with diabetes
mellitus. J Am Vet Med Assoc. 2007;230(7):1011-1017.
41. Shi X, Shi Y, Chen N, et al. Effect of exenatide after short-time inten-
sive insulin therapy on glycaemic remission maintenance in type 2 dia-
betes patients: a randomized controlled trial. Sci Rep. 2017;7(1):2383.
42. Gostelow R, Foracada Y, Graves T, et al. Systematic review of feline
diabetic remission: separating fact from opinion. Vet J. 2014;202(2):
208-221.
43. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC,
Taylor R. Reversal of type 2 diabetes: normalisation of beta cell func-
tion in association with decreased pancreas and liver triacylglycerol.
Diabetologia. 2011;54(10):2506-2514.
44. Højberg PV, Vilsbøll T, Rabøl R, et al. Four weeks of near-
normalisation of blood glucose improves the insulin response to
glucagon-like peptide-1 and glucose-dependent insulinotropic
polypeptide in patients with type 2 diabetes. Diabetologia. 2009;
52(2):199-207.
45. Rudinsky AJ, Adin CA, Borin-Crivellenti S, Rajala-Schultz P, Hall MJ,
Gilor C. Pharmacology of the glucagon-like peptide-1 analog exenatide
extended-release in healthy cats. Domest Anim Endocrinol. 2015;51:78-85.
46. Degn KB, Brock B, Juhl CB, et al. Effect of intravenous infusion of
exenatide (synthetic exendin-4) on glucose-dependent insulin
8 KRÄMER ET AL.
secretion and counterregulation during hypoglycemia. Diabetes.
2004;53(9):2397-2403.
47. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic
actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Metabolism. 2001;50(5):583-589.
48. Schneider EL, Reid R, Parkes DG, et al. A once-monthly GLP-1 recep-
tor agonist for treatment of diabetic cats. Domest Anim Endocrinol.
2019;70:106373.
How to cite this article: Krämer AL, Riederer A, Fracassi F,
et al. Glycemic variability in newly diagnosed diabetic cats
treated with the glucagon-like peptide-1 analogue exenatide
extended release. J Vet Intern Med. 2020;1–9. https://doi.org/
10.1111/jvim.15915




Allen voran möchte ich mich bei meiner Betreuerin Prof. Claudia Reusch für die exzellente 
Unterstützung während meiner Dissertation und die Möglichkeit, diese Arbeit in der Klinik 
für Kleintiermedizin anfertigen zu können, bedanken. Ebenso möchte ich Prof. Eric Zini 
sowie Prof. Thomas Lutz für ihre unermüdliche Unterstützung danken. Ein großer Dank geht 
zudem an meine Coautoren Dr. Angelina Riederer, Prof. Federico Fracassi für ihre Vorarbeit, 
Barbara Contiero für ihre Mühen bei der statistischen Auswertung sowie Prof. Nadja Sieber-
Ruckstuhl und Prof. Felicitas Boretti-Schär für ihre Hilfe bei der Anfertigung dieser Arbeit. 
Nicht zuletzt danken möchte ich meinem Team der Klinik für Kleintiermedizin, meiner 




































Vorname Name   Anna Lena Krämer 
 
Geburtsdatum    08. November 1989 
 
Geburtsort    Winterberg, Deutschland 
 





08/1996-06/2000    Grundschule Aue-Wingeshausen, Bad   
     Berleburg, Deutschland 
08/2000-06/2009 Johannes-Althusius Gymnasium, Bad Berleburg,     
Deutschland 
26. Juni 2009 Abschluss: Abitur (1,1), Johannes-Althusius 





10/2009-03/2015 Studium der Veterinärmedizin, Justus-Liebig Universität, 
Gießen, Deutschland 




Anfertigung der Dissertation 
 
02/2020-12/2020 Anfertigung der Dissertation  
unter Leitung von Prof. Dr. med. vet. Claudia Reusch  
am Departement für Kleintiere, Klinik für 
Kleintiermedizin  
der Vetsuisse-Fakultät der Universität Zürich  





05/2015-04/2016 Internship an der Klinik für Kleintiere, Justus-Liebig 
Universität Gießen, Deutschland 
05/2016-03/2018 Assistenzärztin an der Klinik für Kleintiere- Innere 
Medizin der Justus-Liebig Universität Gießen, 
Deutschland 
04/2018-03/2019 Internship an der Klinik für Kleintiermedizin, Tierspital 
Universität Zürich, Schweiz 
ab 04/2019 Residency ACVIM an der Klinik für Kleintiermedizin, 
Tierspital Universität Zürich, Schweiz  
 
 
 
 
